Low PE Pharma Penny Stock Below 60 Rockets Over 10 Per Cent Today with Heavy Volume; Here’s Why!
Low PE Pharma Penny Stock Below 60 Rockets Over 10 Per Cent Today with Heavy Volume; Here’s Why!

Low PE Pharma Penny Stock Below 60 Rockets Over 10 Per Cent Today with Heavy Volume; Here’s Why!

The company has a market cap of over Rs 400 crore and the stock is up by 16.67 per cent from its 52-week low of Rs 49.20 per share.

DSIJ Intelligence-1 Article rating: 5.0

The company has a market cap of over Rs 400 crore and the stock is up by 16.67 per cent from its 52-week low of Rs 49.20 per share.

Promoters hold 65.99 per cent stake: Low PE pharma penny stock below Rs 60; Company announces significant global expansion and strategic integration
Promoters hold 65.99 per cent stake: Low PE pharma penny stock below Rs 60; Company announces significant global expansion and strategic integration

Promoters hold 65.99 per cent stake: Low PE pharma penny stock below Rs 60; Company announces significant global expansion and strategic integration

The company has a market cap of Rs 287 crore and the stock is up by 6 per cent from its 52-week low of Rs 49.20 per share.

DSIJ Intelligence-1 Article rating: 3.3

The shares of the company have a PE of 12x whereas the industry PE is 36x.

From Rs 6.27 to Rs 30.38 per share: Pharma company received certificate of recognition, One Star Export House from Government of India
From Rs 6.27 to Rs 30.38 per share: Pharma company received certificate of recognition, One Star Export House from Government of India

From Rs 6.27 to Rs 30.38 per share: Pharma company received certificate of recognition, One Star Export House from Government of India

The stock gave multibagger returns of 385 per cent from its 52-week low of Rs 6.27 per share.

DSIJ Intelligence-1 Article rating: 3.1

The stock gave multibagger returns of 385 per cent from its 52-week low of Rs 6.27 per share.

CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA
CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA

CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA

The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.

DSIJ Intelligence-1 Article rating: 5.0

The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 Article rating: 5.0

The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.

Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd
Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd

Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd

The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.

DSIJ Intelligence-1 Article rating: 4.5

The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.

RSS
1234567

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR